Conbercept clinical trials
Conbercept is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Wang Yusheng (1). The most-studied condition is Retinopathy of Prematurity (ROP).
How Conbercept works
All drug targets →- Vascular endothelial growth factor A inhibitor InhibitorTarget: VEGFA vascular endothelial growth factor AChEMBL only
- Vascular endothelial growth factor B inhibitor InhibitorTarget: VEGFB vascular endothelial growth factor BChEMBL only
- Placenta growth factor inhibitor InhibitorTarget: PGF placental growth factorChEMBL only
- Vascular endothelial growth factor C inhibitor InhibitorTarget: VEGFC vascular endothelial growth factor CChEMBL only
- Age-related macular degenerationPhase 3
- Choroidal neovascularizationPhase 3
- Diabetic macular edemaPhase 3
- Macular retinal edemaPhase 3
- Retinal vein occlusionPhase 3
- UveitisPhase 2/3
- RetinoblastomaPhase 2
- Wet macular degenerationPhase 2
- Corneal neovascularizationPhase 1
- Proliferative diabetic retinopathyEarly phase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2108313, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 14582, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Conbercept
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Conbercept
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
NCT06717412 · ClinicalTrials.gov ↗ · Retinopathy of Prematurity (ROP)
|
Not applicable | Recruiting | Wang Yusheng | China |
|
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
NCT06305143 · ClinicalTrials.gov ↗ · Diabetic Macular Edema
|
Phase 4 | Active, closed | Shanghai Eye Disease Prevention and Treatment Center | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Conbercept
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Wang Yusheng | 1 |
| Shanghai Eye Disease Prevention and Treatment Center | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Conbercept trials
How many clinical trials are testing Conbercept?
2 current trials in our China register name Conbercept as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Conbercept trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Conbercept clinical trials?
Wang Yusheng (1) and Shanghai Eye Disease Prevention and Treatment Center (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Conbercept works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Conbercept works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Conbercept (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.